Back to search results
NCT05407415

KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation

Enrolling by Invitation
NAAges 18–90Interventional
Northwestern University
~100 participants
Updated 2025-05-02 on ClinicalTrials.gov
What's tested:Kardia Mobile 6L Device

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To compare healthcare utilization through a questionnaire asking how many office appointments, emergency department visits, and hospital admissions they had within that 6 months.
Measured over 6 Months

Conditions

Atrial Fibrillation (AF)

Explore related trials

Atrial Fibrillation

Where it's being run

1 sites across 1 states
Illinois1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18-90 years of age,
Diagnosis of atrial fibrillation within the last 6 months,
Possession of a smart phone with active cell service,
Physical and cognitive ability to self-record reliable ECG tracings on the KardiaMobile device,
Life expectancy \>12 months.

Exclusion

Resting tremor
Has an intracardiac lead.
Has an implanted loop recorder.
Already has an apple watch, FitBit, or other mobile ECG recorder.
Those who are non-English speaking, pregnant, or a prisoner.

What this trial measures

  • To compare healthcare utilization through a questionnaire asking how many office appointments, emergency department visits, and hospital admissions they had within that 6 months.6 Months

    Kardia Mobile is an FDA approved device that allows one- or six lead ECG recording for 30 seconds using the patient's smart phone. The device has a automated algorithm that interprets the ECG as either sinus rhythm, AF, or unclassified. The intervention arm will be given a KardiaMobile device. They will be instructed on proper device procedure and will use the device with the onset of potential AF-related symptoms (e.g. chest pressure, palpitations, lightheadedness, syncope, shortness of breath, or other symptoms concerning for a cardiac etiology) or when requested to do so by their healthcare provider. Healthcare utilization will be assessed by having the participants in both groups complete a questionnaire asking how many times they used their KardiaMobile device (if randomized to this group) and how many office appointments, emergency department visits, and hospital admissions they had within that six-month period.